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Abstract
Our understanding of the role of the microbiota in our gut and other sites in our body is rapidly emerging and
could lead to many new and innovative approaches for health care. The promise of the potential role of probiotics
for the prevention and treatment of enteric and other infections as an effective solution needs to be realized. The
meeting report summarizes the insights and learning from a recent symposium, “Health Impact of Probiotics -
Vision and Opportunities” conducted in Mumbai by the Yakult India Microbiota and Probiotic Science Foundation
and P.D. Hinduja National Hospital, Mumbai. The symposium reflected its objective of unraveling the potential role
of probiotics for health benefits through presentations and discussions. Experts clearly highlighted the role of
probiotics in improving various aspects of health and in immune modulation. The report also captures the debate
and discussions on the challenges that are likely to be encountered for the use of probiotics in the country.
Introduction
The recent advent of high throughput sequencing tech-
nologies has provided new insights into the composition
and metabolic activities of the intestinal biome. Today it
is recognized that this complex ecosystem is an assem-
blage of more than 1000 species of microorganisms that
exist in harmony (symbiosis) with the host and exert
metabolic activities that virtually parallels an organ
within an organ. While most of these activities are bene-
ficial for the host some may be deleterious, the nature of
effect, being determined by the composition of the flora.
Thus a mutualistic relationship between the beneficial
symbionts and commensals is paramount for the main-
tenance of health and wellbeing with dysbiosis resulting
in clinical disease. It follows that the gut flora can be
manipulated to enhance the beneficial components
which represent a promising strategy for the prevention
and management of various infective and non - infective
disorders.
The symposium started with the welcome address by
Prof. N.K. Ganguly, Distinguished Biotechnology
Research Professor, Department of Biotechnology,
National Institute of Immunology, New Delhi. He gave a
broad introduction to the topic, emphasizing the central
role of the gut flora in the improvement of health. He
stated that of the many proposed interventions, probio-
tics offer immense potential for the prevention of a vari-
ety of diseases. It is therefore not surprising that the
past decade has witnessed tremendous progress in the
area of probiotic research with scientific evidence
quickly accumulating to validate their possible role as
important therapeutic and preventive strategy for gastro-
intestinal diseases, treatment and prevention of allergic
disorders, chronic inflammatory diseases, prevention of
cancers and reduction of respiratory diseases.
Dr. R.A. Badwe, Director, Tata Memorial Cancer Hos-
pital, Mumbai, the Chief Guest reemphasized the signifi-
cant role of the gut flora in maintaining health and
stated that although most of the claims and benefits
associated with probiotic usage are being established,
they mainly represent the findings from the West and
therefore probiotics have found greater acceptance in
that part of the world. The potential for their use in the
developing world has not been adequately investigated.
With the realization that infectious and non-infectious
diseases account for a large majority of deaths annually
in resource limited settings there is optimism about the
ability of interventions such as probiotics to prevent
health disparities. However, since colonization with a
probiotic is dependent on the interplay of multiple fac-
tors in the intestinal mileu, inherent differences in gut
microbial ecology may significantly impact the function-
ing of the probiotic strain and therefore requires a
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to be generated in these settings.
Yakult India Microbiota and Probiotic Science Foundation
Recognizing this need, a group of eminent scientists
formed the Yakult India Microbiota and Probiotic
Science Foundation. This foundation was registered as a
society on 9th November 2011 under the Societies
Registration Act XXI of 1860. The Foundation will aim
at providing a common scientific platform for basic
scientists and clinicians to share and exchange knowl-
edge and views and to expand into newer areas of pro-
biotic research. While the foundation will channelize
International knowledge and expertise in the field of
probiotics it will also promote collaborative research in
the development of probiotics as well as foster and
maintain research links with scientists of similar interest.
The foundation endeavors to do this through an Annual
Probiotic Symposium, which will blend fundamental and
applied research related to the use of probiotics for the
enhancement of human health. With this in mind, the
first symposium of the Foundation with the theme
“Health Impact of Probiotics - Vision and Opportu-
nities” was convened on December 10 and 11, 2011 in
Mumbai.
This report summarizes the discussions and delibera-
tions that ensued over the two days of the symposium.
We hope this will prompt basic scientists, microbiolo-
gists and nutritionists to bring new perspectives to the
science of probiotics and clarify some of the major
issues such as efficacy and acceptable outcomes that
surrounds implementation of probiotic usage in the
country. The challenge of designing randomized con-
trolled trials for understanding and targeting particular
biomarkers and end points for the disease and identify-
ing strain specific health benefits to mark a road map
that may be followed to allow for probiotic usage in the
country needs to be addressed.
Unraveling the effects of probiotics in Gastrointestinal
(GI) disorders
Evidence for the utility of probiotics in the prevention
and treatment of GI disorders in the pediatric population
and in adults was presented by Prof. Philip Sherman, Pro-
fessor of Pediatrics, Microbiology and Dentistry, Research
Institute, University for Sick Children, University of Tor-
onto, Canada and Dr. Philip Abraham, Senior Consultant
Gastroenterologist and Hepatologist at P.D. Hinduja
National Hospital, Mumbai.
Presenting global evidence for their utility in children,
Prof. Sherman illustrated that evidence through rando-
m i z e dc o n t r o l l e dt r a i l sh a v ed e m o n s t r a t e dt h a tc e r t a i n
probiotic strains are more effective than placebo in a
variety of conditions affecting the gastrointestinal tract.
Multiple meta-analyses indicate effectiveness in reducing
the duration of acute enteritis in pre-schoolers and in
reducing the frequency of necrotizing enterocolitis in
pre-term babies [1,2]. There is some evidence support-
ing the use of selected probiotic agents to either prevent
or treat antibiotic-associated diarrhea and Clostridium
difficile infection. In Prof. Sherman’s opinion, more data
is, however, necessary to confirm the efficacy of probio-
tic agents, either solely or in combination, in the man-
agement of various chronic inflammatory bowel diseases
and in allergic enterocolitis. According to him, in future,
probiotic strains are likely to be chosen for use in speci-
fic clinical settings based on their underlying mechan-
ism(s) of action. There is also the possibility of
developing specific disease targeted designer probiotics,
he added. Elaborating further, he opined that issues
related to optimal dosages, time of ingestion, single ver-
sus combination formulations, maintenance of viability,
and the merits of employing probiotic-derived products
would only be answered by undertaking additional
research in the field.
Presenting the evidence for their use in adults, Dr.
Philip Abraham, Consultant Gastroenterologist, P.D.
Hinduja National Hospital, Mumbai, India, stated that
probiotics may be useful in preventing antibiotic-asso-
ciated diarrhoea, including those caused by Clostridium
difficile. They are also efficacious in reducing the sever-
ity and duration of other adult and pediatric diarrhoeas
especially those caused by rotavirus. However, their role
in prevention of traveler’s diarrhoea is equivocal and
hence limits their use in this condition.
Dr. Abraham further elaborated on the evidence for
their use in chronic and acute conditions specifying that
there is increasing evidence indicating that probiotics
are an effective adjunct to triple therapy in the eradica-
tion of Helicobacter pylori infection, exhibiting enhanced
eradication rates and reductions in adverse events. He
added that although probiotics have shown benefit in
improving symptoms of Irritable Bowel Syndrome, cur-
rent clinical practice guidelines do not recommend their
use in treatment regimens. In Inflammatory Bowel Dis-
eases, results are variable although positive benefit has
been shown, in preventing relapses in Ulcerative Colitis
and Crohn’s disease, the most consistent and favourable
result being in the prevention and treatment of the pou-
chitis. Data for the prevention of colon cancer in high-
risk individuals however, requires long-term intervention
and is therefore hard to come by. There is favourable
evidence in animal studies and some evidence in
humans, that probiotics can reduce cell proliferation in
patients with colonic adenoma [1]. Previous studies sug-
gest that clinical improvement may occur in patients
with hepatic encephalopathy due to reduction of fecal
urease activity and blood ammonia concentration.
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countries?
India continues to face disproportionate morbidity and
mortality due to diarrhoeal diseases. The 2008 statistics
indicate that 18% of the global child diarrhoeal deaths
and 77% of diarrhoeal deaths of children in Southeast
Asia were from India [3]. Using both culture dependent
and culture independent methods for 26 different
enteric pathogens, Dr. G.Balakrish Nair, Executive
Director of the Translational Health Science and Tech-
nology Institute, Gurgaon, Haryana, provided evidence
that more than two thirds of the patients with diarrhoea
admitted to the Infectious Diseases Hospital in Kolkata
excreted more than one enteric pathogen and, some of
them excreted as many as six pathogens. Several com-
munity-based diarrhoeal surveillance studies conducted
in the urban slums of Kolkata, have also shown that
enteric pathogens found amongst cases with varied age
and socio economic status, matched healthy children
sampled as controls thereby substantiating that the
extent of exposure to fecal bacteria and enteric patho-
gens in impoverished settings is huge. This results in
tropical enteropathy, increased permeability and modest
malabsorption [4]. The consequence of these conditions
include impaired nutrient utilization because of altered
microbiota, poor oral vaccine uptake, diminished protec-
tive efficacy of these vaccines as compared to that in
developed countries and requirement of higher oral vac-
cine dose in the impoverished settings [5]. Available
data from developed countries suggest that probiotics
are effective against diarrhoea of diverse causes and fur-
nish the evidence for the use of probiotics in prevention
and treatment of diarrhoea. In stark contrast, in devel-
oping countries, probiotics need to be effective against a
complex backdrop of child undernutrition, ingestion of
high concentration of fecal bacteria because of poor
sanitary conditions, tropical enteropathy, hyperperme-
able gut, reduced nutrient absorption and growth falter-
ing. Using this as the background, Dr. Nair opined that
probiotics may serve as an ideal intervention strategy to
improve gut microbiota and counter enteric pathogens
present in such disease endemic areas. Appropriately
conducted randomized trials would decide the future
significance of probiotics in impoverished settings and
would also help to furnish information on the mechan-
ism of action of probiotics in settings quite different
from the sanitized West.
Dr. Nair shared the findings of a recent study on 3758
children aged 1-5 years in an urban slum in Kolkata
which evaluated the occurrence of first episodes of diar-
rhoea as primary outcome and composition of fecal
microbiota as the secondary outcome. The results of the
study revealed that daily intake of a probiotic strain,
Lactobacillus casei strain Shirota played an important
role in prevention of acute diarrhoea in young children
in a community setting. These results show a significant
protective effect (14%, 95% CI: 4-23%) of the probiotic
on acute diarrhea in children during the 24 week period
with only 608 children in the Probiotic group (0.88 no.
of cases/child/year) developing diarrhoea as compared
to 674 children in the Nutrient group (1.029 no. of
cases/child/year) during the 24 week study period [6].
Elaborating on the same study Dr. Koji Nomoto,
Associate Director, Yakult Central Institute for Micro-
biological Research, Tokyo, presented details of the var-
iation in the composition of the gut flora in the
diarrhoeal samples from the children in the probiotic
and nutrient groups. Analysis of the composition was
done using Yakult Intestinal Flora - SCAN (YIF-
SCAN
®) which is based on reverse transcription quanti-
tative PCR (RT- qPCR) using specific primers that target
bacterialr RNA molecules [7-9]. Dr. Nomoto shared
results which revealed that the gut flora was disrupted
in the diarrhoeal samples in comparison to the non
diarrhoeal samples and how these aberrations in the gut
flora could be restored by including a probiotic
intervention.
According to Dr. Shinjini Bhatnagar, Professor, Pedia-
tric Biology Centre at the Translational Health Science
Technology Institute, Gurgaon, Haryana, at present,
there is a lack of sufficient evidence for the use of pro-
biotics in the treatment of acute diarrhoea in the devel-
oping world and large randomized controlled studies
using specific probiotic regimes in defined groups of
children with uniform definitions for clinical outcomes
would definitely pave the way forward. She stated that
this would help to advance the understanding of specific
probiotics in Indian settings where breast feeding rates
are higher and microbial colonization of the gut is dif-
ferent. In her opinion, these studies should focus on
evaluating possible interactions when probiotics are
used as combinations or with other antimicrobials/
drugs/zinc.
Probiotics in mucosal immunology by which mechanisms
can probiotics be clinically effective?
As a key physical interface to the external environment,
the gut epithelium is a highly dynamic and multi func-
tional barrier. In health, a delicate homeostasis is main-
tained at intestinal surfaces between the micro
organisms present and the host tissues to finely tune
responses appropriate to native commensals versus
potential pathogens. The protective mucus layer in the
intestine controls unchecked bacterial proliferation and
also serves as a feedback system to regulate both innate
and adaptive immune responses [10]. Dr. S.V. Chiplun-
kar, Principal Investigator, ACTREC, Tata Memorial
Centre, Mumbai discussed the various in vitro and in
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probiotics are able to modulate the immune system to
protect against infectious diseases and cancer.
She stated that probiotic supplementation leads to a
significant increase in phagocytic activity of blood
monocytes, granulocytes and augments NK cell activity
though a variety of mechanisms. Major gaps, she said,
exist in our knowledge about the mechanisms by which
probiotics modulate antitumor immunity. Further, dif-
ferent probiotic strains vary in their ability to modulate
the immune system and therefore efficacy of each strain
needs to be carefully demonstrated through rigorously
designed randomized, double-blind, placebo-controlled
studies. In conclusion, she emphasized that probiotics
play an important role in potentiating innate and
acquired immune responsiveness which can be further
exploited for modulating anti-cancer immunity [11].
Extending these deliberations further Dr. Masanobu
Nanno, Associate Director at the Yakult Central Insti-
tute for Microbiological research, Tokyo presented the
significant role of Lactobacillus casei strain Shirota
(LcS) as an important immune modulator that has the
ability to prevent recurrence of cancers. This strain of
bacteria, he shared, has more than 75 years of research
to back its scientific efficacy and has demonstrated a
beneficial role in the prevention of recurrence of super-
ficial bladder cancer following transurethral resection
[12]. The same strain of bacteria according to him was
also effective in preventing the recurrence of colorectal
cancer with moderate or severe atypia in subjects who
had undergone surgical resection of colon polyps [13].
He elaborated that for understanding the mechanism of
action of LcS especially in the prevention of colon can-
cer, the effect of LcS on colitis associated cancer models
was examined where it was observed that administration
of LcS prevented the reccurrence of colon cancer by
down-regulating IL - 6 production in the colonic
mucosa [14]. NK cell activity was also restored in
HTLV-I-associated myelopathy patients and the cyto-
toxic activity increased significantly in healthy subjects
who consumed LcS for a period of three weeks. In vitro
analysis revealed that LcS-induced activation of NK cells
is mediated by IL-12 produced by phagocytic cells.
Therefore, establishing the fact that LcS plays a signifi-
cant role in immune modulation which may be the
mechanism for the prevention of recurrence of cancers.
Professor Yuichiro Yamashiro from the Probiotics
Research Laboratory of Juntendo University Graduate
School of Medicine, Tokyo, Japan elaborating two stu-
dies of LcS supplementation shared how the administra-
tion of LcS, decreased febrile episodes (> 37°C) and the
duration of such episodes, reduced constipation fre-
quency and decreased development of diarrhoea thereby
bestowing health benefits to elderly people at a Health
Service Institution. Data presented by him evidenced
that investigation of faecal bacteria disclosed significant
increment in numbers of faecal Bifidobacterium. Methi-
cillin-resistant Staphylococcus aureus and methicillin-
resistant coagulase-negative Staphylococci were detected
from 1 case and from 5 cases, respectively, out of 42
cases before the clinical study, were not isolated after
the administration of LcS [15]. Professor Yamashiro also
illustrated that B. breve was very effective in the treat-
ment of mucositis (also referred to as mucosal barrier
injury), one of the most debilitating side effects of che-
motherapy treatment and was also very effective in pre-
venting NEC and infection in preterm infants [16].
Bacterial vaginosis and probiotics
Dr. P. Hemalatha of the National Institute of Nutrition
(NIN), Hyderabad presented information on the use of
probiotics in Bacterial Vaginosis (BV), one of the most
common vaginal syndrome afflicting premenopausal and
pregnant women. Dr. Hemalatha indicated that since
reduction of lactobacilli and increase in pH are the
main pathogenesis of BV, probiotics are being explored
for their role in restoring the vaginal flora. Meta-analysis
of several trials with antibiotics have shown a cure rate
of 60% but oral lactobacilli treatment followed by anti-
biotics for treatment of BV have shown more than 80%
cure rate after one month. Further, a Cochrane meta-
analysis on efficacy of lactobacilli for the treatment of
BV showed beneficial outcome with oral probiotics
combined with metronidazole or estriol preparation sug-
gesting the need to combine antibiotics with lactobacilli
while aiming to treat BV. Sharing findings of a double-
blind, randomized, placebo-controlled study conducted
by NIN on 67 healthy, non pregnant, married women
aged 20 to 40 years from urban slum with BV (Nugents’
score > 7) where a vaginal tablet containing at least 10
[9] viable Lactobacilli (L. brevis, L. salivarius subsp. Sali-
cinius, L. plantarum) inserted into the vagina daily at
bedtime for 8 days demonstrated a cure rate of nearly
80%. Cervico-vaginal lavage (CVL) was collected to mea-
sure the concentrations of tumor necrosis factor (TNF)-
a, interleukin (IL)-1 b and IL-6 by Quantitative Milli-
plex ELISA kit. It was interesting to note significant
r e d u c t i o ni nI L - 1 b and IL-6 proinflammatory cytokines
with lactobacilli treatment, while an increase in IL-6
cytokine was observed with pH adjustment tablet. This
is the first study demonstrating the effect of lactobacilli
treatment on local proinflammatory cytokines [15].
Merits of this study include control on time of sam-
pling and initiation of treatment, which was during the
same phase of the menstrual cycle in all the subjects.
Therefore, hormonal influence could be ruled out on
the effectiveness of the lactobacilli treatment. Attrition
rate was also minimum all through. The major
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for the treatment of BV and using a pH adjustment
tablet instead of a placebo. The vaginal tablet containing
three strains of lactobacilli used in the study discussed
was well tolerated and no side effects were reported,
which was similar to the earlier findings. The strains of
lactobacilli used in the study were however, chosen not
so much for their ability to adhere and colonize at high
levels but primarily because, the preparation when used
in Italy showed 100% efficacy. However, as suggested
earlier, longer and repeated treatments could be sug-
gested for better out come and must be treated with
antibiotics prior to lactobacilli instillation.
Which is the best carrier matrix for a probiotic?
A question that often comes up in most deliberations is
about the choice of the carrier matrix for the delivery of
the probiotic strain. Dr. A.K. Srivastava, Director,
National Dairy Research Institute, Karnal, India stated
that dairy based foods, particularly traditional fermented
milks like dahi, yoghurts and dairy beverages which are
already an integral part of the traditional Indian diet
and are considered functional foods can be explored as
the most appropriate carriers of probiotics to optimally
express their health promoting functions in the gut.
Dairy based probiotic foods represent the largest seg-
ment accounting for nearly 65% of the total world func-
tional food market. Presently, dairy based probiotic food
industry is firmly placed at the global level completely
dominated by Europe, Japan and USA. Although, India
is yet to make a mark in the probiotic product develop-
ment in a big way, major global leaders like Yakult and
Nestle, and National player: Mother Dairy have underta-
ken the formidable task of introducing a new market for
probiotics in India having covered much ground in a
short span. He emphasized that to launch Indian pro-
biotic products in the country, vital issues such as devel-
oping novel indigenous probiotic strains with proven
functional efficacy both in vitro and in vivo, their inter-
compatibility, effective dosage and colonization in the
human gut, technological parameters during processing
of the product, encapsulation and their impact on stabi-
lity, survival and viability of probiotic strains along with
validation of health claims and safety using different ani-
mal models as well as in human subjects through clini-
cal studies would need to be worked out. Future success
of probiotic formulations, in his opinion, will depend on
consumer’s acceptance.
Dr. B.S. Ramakrishna, Professor and Head, Depart-
ment of Medical Gastroenterology, Christian Medical
College, Vellore stated that although the FAO/WHO
criteria provide excellent general principles for the char-
acterization and evaluation of probiotics in food, they
fall short of prescribing the specific tests that may need
to be done in an individual case [17]. Given that meta-
genomic studies and metabolomic profiling of the
microbiota and the human host have provided major
advances in the ability to characterize the molecular
aspects of the intestinal microbiota and understand the
human-microbiota interaction, it can be hoped that
these will eventually translate to more robust in vitro
and animal testing procedures that can precede human
trials and provide the additional evidence for health
benefits. In addition, he emphasized that the health sys-
tem would need to be harnessed in a way that would
allow the reporting and capture of any adverse events
that can be potentially related to use of probiotic foods
or drugs and provide post-market surveillance of the
kind available in the developed world.
Dr. Gianfranco Grompone, Senior Scientist, Danone
Research, Institute Pasteur, Montevideo extended the
discussion further and illustrated in a very exciting pre-
sentation entitled “Reshaping In Vitro Tests for Probio-
tics: Increasing Predictability by a Multi-Dimensional
Approach” how predictability can be improved from in
vitro tests for better selection and characterization of
potential anti-infectious probiotic strains [1]. Presenting
a multi-dimensional integrative approach applied by him
and his team to screen 100 LAB strains in vitro, they
developed novel host-bacteria heterotypic co-culture
systems with Intestinal Epithelial Cells, Peripheral Bone
Monocyte Cells and Dendritic cells that were incubated
with strains of Lactobacillus, Bifidobacterium or Strepto-
coccus and cytokine secretion profiles determined. In
addition mannose adhesion and direct pathogen-inhibi-
tion on agar plates were tested. All the results were
compiled and analyzed by Principal Component Analysis
in order to rank and compare the strains [18]. Two
strains displayed distinct activity profiles of great inter-
est for probiotic application, one for anti-inflammatory
effect and the other one for anti-infectious purpose. Pre-
liminary results, he shared, show anti-infectious effect in
vivo using mice infection models.
Conclusion
It is perhaps most appropriate to conclude with the
statement made by Professor Yamashiro who stated that
according to World Population Prospects of the UN, we
are currently witnessing a transition from high fertility
and mortality rates to low birth rate and death. This
trend reflects the size and structure of regional popula-
tions leading to longevity and shrinking of child popula-
tion. The results of studies conducted by Professor
Yamashiro and his colleagues highlight the role that
probiotics will play in the future and the benefits that it
will bring for changing structure of world population.
Health decision makers have an opportunity to make
important strides in the area of probiotic research. A
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accrue at a local level is needed to ensure that they are
safely, swiftly and successfully delivered to everyone who
needs them.
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